Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 23, 2019updated 23 Dec 2019 10:22am

Medtronic to offer Viz.ai’s AI stroke detection software in US

Irish medical technology firm Medtronic has agreed to distribute artificial intelligence (AI)-based stroke care solutions provider Viz.ai’s new technology across US centres.

Irish medical technology firm Medtronic has agreed to distribute artificial intelligence (AI)-based stroke care solutions provider Viz.ai’s new technology across US centres.

Viz.ai’s software, which holds US Food and Drug Administration (FDA) clearance, has been designed to detect suspected large vessel occlusion (LVO) strokes.

It can be linked to hospital computed tomography (CT) scanners and uses advanced deep learning to automatically notify specialists about a suspected LVO stroke.

Within minutes, the software sends radiological images directly to stroke specialists’ smartphones.

The technology is expected to optimise stroke care and decrease time-to-treatment for better patient outcomes.

Under the terms of the deal, Medtronic will distribute Viz.ai’s LVO detection and triage software services that have marketing authorisation in the US.

Content from our partners
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Viz.ai technology is available in more than 200 hospitals and aims to expand to all stroke centres.

Viz.ai co-founder and CEO Dr Chris Mansi said: “As the largest medical device company in the world, Medtronic is an ideal partner to help physicians access Viz.ai’s cutting-edge technology to ensure as many patients get the care they need as quickly as possible.”

Of all patients who suffer from an LVO in the US, only 15% are estimated to undergo a mechanical thrombectomy procedure that removes blood clots, noted Medtronic.

In a study conducted at two sites, Viz LVO demonstrated the ability to alert the stroke specialist earlier than standard in 95.5% of true positive cases. The software was able to save an average of 52 minutes.

Medtronic Neurovascular business vice-president and general manager Stacey Pugh said: “We are excited about this partnership because Viz.ai’s technology has the potential to significantly reduce the time it takes for patients suspected of LVO stroke to receive the care they need.

“Viz.ai’s software coupled with our network is going to increase access to needed therapies. It greatly complements our existing portfolio.”

Currently, the Irish company provides the Solitaire Platinum revascularisation stent designed to retrieve clots from occluded blood vessels in the brain of patients having an acute ischemic stroke (AIS) due to an LVO.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU